ABBV
CALLS ▲AbbVie Inc.
$294.89
+1.41%delayed
News – · Trend ▲ · above call trigger ▲
Expected move (1d)
▼ $288.49to$301.29 ▲
ATR ±$6.40 (+2.17%)Implied ±$10.52 (+3.57%)
Entry Reference
Price / prev close$294.89 / $290.79
Day range$291.01 – $298.74
52-wk range$190.75 – $298.74(96%)
Volume vs avg1.45×
ATR (14d)$6.40
MA 8 / 21$287.55 / $280.74
MA 50 / 200$269.29 / $237.10
Call ▲ / Put ▼ trigger$292.30 / $289.28
+1 / +2 ATR$301.29 / $307.69
-1 / -2 ATR$288.49 / $282.09
Support: 291.40 278.01 269.39
Resistance: -
Near-the-money contracts
exp 2026-11-06Calls
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 287.5 | $9.68 | 40% | 0.70 | -0.45 | 91 |
| 290 | $7.82 | 35% | 0.65 | -0.41 | 782 |
| 292.5 | $6.40 | 36% | 0.58 | -0.44 | 18 |
| 295 | $5.05 | 34% | 0.51 | -0.43 | 83 |
| 297.5 | $4.10 | 36% | 0.44 | -0.45 | 23 |
| 300 | $2.86 | 32% | 0.36 | -0.37 | 205 |
Puts
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 285 | $1.81 | 36% | -0.23 | -0.32 | 20 |
| 287.5 | $2.42 | 36% | -0.28 | -0.36 | 64 |
| 290 | $3.12 | 35% | -0.35 | -0.38 | 93 |
| 292.5 | $3.85 | 35% | -0.41 | -0.40 | 14 |
| 295 | $5.47 | 39% | -0.49 | -0.45 | 24 |
| 297.5 | $6.75 | 40% | -0.55 | -0.46 | 3 |
Δ = delta (≈ probability ITM), θ/day = daily time decay, IV = implied vol. Greeks computed via Black-Scholes from Yahoo IV.
Recent news
- Dividend Champion, Contender, And Challenger Highlights: Week November 15h ago
- AbbVie (ABBV) Q3 2026 Earnings Call Transcript6h ago
- Q3 earnings round-up: AstraZeneca, AbbVie, Kenvue7h ago
- LLY, ABBV Stocks Hit All-Time High – Here’s What’s Driving Investor Enthusiasm Today8h ago
- What AbbVie (ABBV) Said on Its Q3 Earnings Call9h ago
- AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views12h ago
- $250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends12h ago
- ABBV Beats on Q3 Earnings & Sales, Stock Rises on Raised '26 EPS View13h ago
- AbbVie Inc. (ABBV) Q3 2026 Earnings Call Transcript13h ago
- CDs Offer Fixed Interest. AbbVie Offers a Growing Dividend. Which Should Retirees Choose?13h ago
- Pre-Markets Spooked on Questions Regarding AI, Oil Prices14h ago
- AbbVie: Why I See More Upside After Q314h ago
Reference data only. Not a recommendation. Greeks and expected-move figures are estimates, not certainties. You confirm all entries and contracts in TradingView and Charles Schwab.